CLRB ▲ +4.9% - Cellectar Biosciences, Inc.
$CLRB CLRBW CLRBZ - Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
27-OCT-2026 07:15 AM ET
Share this post
More filings for $CLRB
CLRB ▲ +6.7% - Cellectar Biosciences, Inc.Oct 15, 2026CLRB ▲ +0.5% - Cellectar Biosciences, Inc.Sep 29, 2026CLRB - Cellectar Biosciences, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026CLRB - Cellectar Biosciences, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026CLRB - Cellectar Biosciences, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026CLRB - Cellectar Biosciences, Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026
View full $CLRB filing history →💬 Comments
Loading comments…
Leave a comment